March 31, 2017
Agilvax Selected for Springboard Health Innovation Hub 2017
Albuquerque, NM, April 06, 2017 – Federica Pericle, PhD, MBA President and CEO of Agilvax was accepted into the 2017 Pharma class of the Springboard Health Innovation Hub. Springboard’s highly competitive Health Innovation Hub is a year-long program for women-led healthcare and life science companies seeking seed and growth funding to fuel expansion and product development. Agilvax is excited to interact and learn from a team of targeted advisors and participate in the multiple workshops and presentation sessions throughout the year that will introduce the company to influencers, active investors, and potential strategic partners. Springboard has a strong track record of mentoring successful companies. Since its inception 15 years ago 661 companies have come through the Springboard program, with an impressive 86% funding rate and over $7.5B in capital raised. Agilvax is honored and thrilled to have been chosen to join the prestigious Springboard Class of 2017 and looks forward to gaining invaluable guidance and exposure.
Agilvax is a biotechnology company that develops innovative cancer therapeutics and vaccines using its proven virus-like particle (VLP) platform technology. Agilvax’s lead immunotherapy product, AX09, is intended for the treatment of triple-negative breast cancer (TNBC). The Company is also developing vaccines against infectious diseases with a high unmet clinical need, such as respiratory syncytial virus (RSV). Agilvax has a solid intellectual property portfolio covering products (composition of matter and method of use) and the discovery platform. The Company was formed in 2011 and has raised just over $4 million in equity investment (Series A). The company has also secured collaborations with government (NIH) and several pharmaceutical partners. Agilvax is headquartered in Albuquerque, NM with offices in El Paso, TX.